Trial site
Integrative Skin Science and Research
Sacramento, California 95815, United StatesNot linked to an institution yet
- 12running trials
- 7closed trials
The trials here
What the 19 trials at this site are about, from their registry records.
- Phase
- Phase 313 trials
- Phase 25 trials
- Phase 41 trial
- Status
- Active, not recruiting9 trials
- Completed5 trials
- Recruiting3 trials
- Terminated2 trials
- Lead sponsor
- Amgen3 trials
- Janssen Research & Development, LLC3 trials
- Alumis Inc2 trials
- Eli Lilly and Company2 trials
- Pfizer2 trials
- and 7 more
Running trials
Recruiting
Obtaining Descriptive Classifications of Pruritus and Assessing Change in Pruritus Over Time in Atopic Dermatitis Patients Using Topical Roflumilast Cream.
NCT07560618· Phase 4· Integrative Skin Science and Research· Source
Contact: Nasima Afzal
Recruiting
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
NCT07599813· Phase 2· Apollo Therapeutics Ltd· Source
Contact: Sydney Fong
Active, not recruiting
A Study to Investigate Safety and Efficacy of Tapinarof Cream, 1% in Participants Ages 3 Months to < 24 Months With Atopic Dermatitis
NCT07265479· Phase 3· Organon and Co· Source
Active, not recruiting
A 16-Week Study to Learn About the Study Medicine Called Ritlecitinib in Adults With Long Lasting Painful Red Skin Lumps, Known by the Medical Term, Hidradenitis Suppurativa, or HS.
NCT07228390· Phase 2· Pfizer· Source
Recruiting
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
NCT07116967· Phase 3· Bristol-Myers Squibb· Source
Contact: Raja Sivamani, Site 0316
Active, not recruiting
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
NCT06934226· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
NCT06846541· Phase 3· Alumis Inc· Source
Active, not recruiting
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
NCT06143878· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2
NCT06072183· Phase 3· Pfizer· Source
Active, not recruiting
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
NCT06095115· Phase 3· Janssen Research & Development, LLC· Source
Active, not recruiting
A Study of Lebrikizumab (LY3650150) in Participants 6 Months to <18 Years of Age With Moderate-to-Severe Atopic Dermatitis
NCT05559359· Phase 3· Eli Lilly and Company· Source
Active, not recruiting
Evaluating Safety and Efficacy of ADX-914 in Patients With Moderate to Severe Atopic Dermatitis (SIGNAL-AD)
NCT05509023· Phase 2· Q32 Bio Inc.· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error